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Objective.TheprevalenceofCeliacDisease(CD)ishighinIran,andevaluationofCDisnotpartoftheroutinescreeningprocedure
for dyspeptic patients; therefore, cases of occult CD may be missed. This study aimed to investigate the prevalence of occult CD
among dyspeptic patients who presented at a gastroenterology clinic in the Western region of Iran. Methods. In this descriptive,
cross-sectional prospective study, patients who had a history of at least 12 weeks of upper abdominal discomfort were eligible to
participate in the study during a 14-month recruitment period. Patients with a clinical or paraclinical data in favor of organic
causes were excluded from the study. Enrolled patients were screened for IgA antiendomysium antibody (EMA) and IgA antitissue
transglutaminase antibody (tTG). Those who screened positive for EMA/tTG received a conﬁrmatory diagnostic biopsy for Marsh
classiﬁcation of CD. Results. From 225 potential participants with dyspepsia, 55 patients were excluded due to having explainable
organic causes. The study sample included 170 patients with “functional dyspepsia.” Mean age of participants was 31 years and
55.8% were female. Twelve patients (7%) had positive tests (EMA/tTG), of which 10 were female (83.4%). According to Rome
II criteria, all twelve patients with positive tests had “dysmotility type dyspepsia.” Based on Marsh classiﬁcation, six patients
were consistent with “Marsh I,” four with “Marsh II,” and two with the “Marsh III” classiﬁcation. Conclusions. In this study,
the prevalence of CD in dyspeptic patients was high. As a result, this study suggests that screening by serology tests (EMA/tTG) is
justiﬁable for the detection of CD among functional dyspeptic patients in the tertiary centers in our country.
1.Introduction
Celiac disease (CD) is a genetic, inﬂammatory digestive
disease triggered by ingestion of gluten-containing foods,
which damage the small intestine and interfere with the
absorption of nutrients from food [1]. CD has protean
manifestations almost all of which are secondary to nutrient
malabsorption and causes symptoms throughout the body,
including abdominal bloating and pain, chronic diarrhea,
vomiting, constipation, weight loss, and development of
gastrointestinal cancer. It is prevalent in both adults and
children, but is more frequent in women than men with
F/M ratio 2:1 [2]. In the past, CD was thought to be
a European disease, but recently, in developing countries,
including the Middle East, Gluten intolerance CD has
become a widespread public health problem in both the
general population and in at-risk groups [3–5].
Nevertheless, nowadays only a small percentage of CD
patients present with classic malabsorption syndrome. Many
of these patients are oligosymptomatic, and usually present
with a mild or silent form of the disease; a phenomenon
called “celiac iceberg” by researchers. “Celiac iceberg”2 Gastroenterology Research and Practice
represents people at risk for celiac disease by virtue of their
genes [3]. In the Middle East, the prevalence of the silent
form in the general population has been estimated between
0.6%–1% [5, 6].
Since the ﬁrst report of its atypical presentation [7],
many investigators have tried to recognize its presentation
within other intestinal and extraintestinal disorders [3, 8, 9].
Unrecognized cases of CD have the potential to cause severe
complications, such as ulcerative, jejunoileitis malignancy,
and autoimmune disease [8–10]. Early detection of this
disease can prevent many of its unwanted complications.
Therefore, eﬀorts to recognize the silent or atypical forms
of CD among high-risk groups should continue. The
prevalence of CD among high-risk adult Iranian patients
(i.e., diabetes mellitus type 1) who were screened for its
subclinical presentation was reported between 2.4%–10%
[11]. Among a sample of 2000 healthy Iranian blood donors,
the prevalence of gluten sensitivity was estimated at 0.6%
[5]. In a report from Turkey, among children with short
stature, 55.3% screened positive for the silent form of CD
[10]. Studies with regard to dyspeptic patients have been
limited [12, 13]. In a study that evaluated the prevalence
of CD in dyspeptic patients, including both functional and
organic causes, researchers found a prevalence of 1.4%
[12]. Dyspepsia is a common disease and aﬀects about
40% of the general population. Even after its diagnosis, the
cause of 60%–70% of these cases cannot be determined,
and are generally labeled “functional dyspepsia” [12–17].
Pathological changes in the autonomous system have been
suggested as the mechanism underlying the pathophysiology
of functional dyspepsia subgroups. Antibody against enteric
nervous system may play a role in functional symptoms
seen in CD [18]. However, there are still many unresolved
pathological aspects in the ﬁeld of functional dyspepsia.
Therefore, the speciﬁc aim of this study was to investigate the
prevalence of occult form of CD among functional dyspeptic
patients who presented to a gastroenterology clinic located
in the Northwestern region of Iran. Findings from this study
could help physicians to recognize the clinical presentations
of celiac disease (i.e., classical, atypical and silent forms), and
therefore pursue subsequent required referral and treatment.
2. Methods
In this prospective cross-sectional study, during a period
of 14 months (October 2007 to December 2008), all
patients with dyspepsia who were referred to our referral
gastroenterology clinic in Imam Reza hospital, an aﬃliate of
Kermanshah University of Medical Sciences in the western
region of Iran, were recruited for participation in the study.
Inclusion criteria included history of at least 12 weeks of
upper abdominal discomfort. Both genders were eligible to
participate, and there were no inclusion criteria for age.
During the recruitment period, the objective of the study
was explained to the potential participants, and informed
consent was obtained. Patients with a history of CD in their
family and clinical or paraclinical data in favor of GERD,
IBS, drug usage (NSAID), pancreatic or gallbladder disease
Table 1: Organic causes among the enrolled dyspeptic patients.
Diagnosis N (%)
Peptic lesions 35 (64)
Esophagitis 8 (15)
Erosive gastritis 11 (20)
Duodenal ulcer 10 (18)
Gastric ulcer 6 (11)
Malignancy 7 (12)
Adenocarcinoma 5 (71.4)
Gastric lymphoma 2 (28.6)
Miscellaneous 13 (24)
Gastric polyp 4 (30.7)
Telangiectasia 2 (15.3)
Heterotopic pancreas 1 (7.69)
Leiomyoma 2 (15.3)
Portal gastropathy 1 (7.69)
Lymphocytic gastritis 2 (15.3)
Cystic fundal hyperplasia 1 (7.69)
Total 50 (100)
Table 2: Demographic data of patients with functional dyspepsia.
Mean age (yr) ±SD 31 ±3.4
Age range (yr) 12–75
Female 95 (55.8%)
Male 75 (44.1%)
Ulcer-like 51 (30%)
Dysmotility 85 (50%)
Nonspeciﬁc 34 (20%)
Positive EMA/tTG 12 (7%)
were excluded from study. Total abdominal sonography was
done by an expert radiologist. Endoscopy was performed via
videoendoscope (Pentax-EG2930K, Japan). From225 poten-
tial dyspeptic participants with Rome II criteria, 55 patients
were excluded due to having explainable gastrointestinal
organic causes (Table 1). One hundred and seventy (170)
patients who had no explainable organic cause with possible
diagnosis of functional dyspepsia were enrolled in the study
and classiﬁed into three subtypes according to Rome II
criteria: (1) ulcer-like dyspepsia, where the predominant
symptom is pain centered in the upper abdomen; (2)
dysmotility-like dyspepsia, characterized by upper abdomi-
nal fullness, early satiety, bloating, or nausea, with no report
of painful discomfort in the center or upper abdomen; (3)
unspeciﬁed dyspepsia, where symptoms do not fulﬁll the
criteria for ulcer-like or dysmotility-like dyspepsia. All three
groups were screened for IgA antiendomysium antibody
(EMA) and IgA antitissue transglutaminase antibody (tTG),
which were detected by the ELISA test (BMD, Marne la
Vallee, France). In patients with positive EMA/tTG, titer
(>20iu/mL), re-endoscopy was performed and at least four
biopsy fragments from the distal portion of the duodenum
were taken, ﬁxed in 10% formaldehyde, and sent to the
pathology lab. The pathologist was unaware of the clinicalGastroenterology Research and Practice 3
or endoscopy diagnosis of the patients. The small intestinal
biopsy is considered the gold standard for diagnosis of
CD using the modiﬁed Marsh UEGW criteria [14] for the
analysis of fragment. Descriptive statistics were performed
using SPSS for Windows (version12).
3. Results
Table 1 presents the organic causes for the enrolled patients
who were excluded from study. Table 2 presents the demo-
graphic characteristics and prevalence of CD among the
functional dyspeptic subtypes. A majority of the enrolled
samplewerefemale(55.8%).PositiveEMA/tTGwasreported
among 7% of the sample (n = 12 patients), of whom 10 were
female (83.4%). All of the patients with EMA/tTG (n = 12)
had “Dysmotility type dyspepsia,” according to the Rome
II subclassiﬁcations. Based on Marsh classiﬁcation, six of
these patients were consistent with “Marsh I,” four were with
“Marsh II,” and two with the “Marsh III” classiﬁcation.
4. Discussion
CD is a curable disease; however, it poses a challenging
public health problem in developing countries [3]. Previous
studies have reported high prevalence of CD among patients
with organic or functional dyspepsia [13, 14], but to our
knowledge, this is the ﬁrst study that reports the prevalence
of CD in dyspeptic patients according to Rome II subclassiﬁ-
cation.Overthelastdecade,clinicalresearchershaverevealed
that CD is no longer a rare disease, and its subclinical or
atypical form is quite prevalent [3]. Therefore, it has been
recommended to detect the symptoms of this curable disease
in its initial presentation in order to prevent its unwanted
complications. Three approaches have been suggested for
CD screening [3]. One option is to perform a biopsy on
all patients who undergo upper endoscopy [2, 17]. This
approach has been criticized due to the costly nature of this
procedure. The second approach suggests using magni-
ﬁcation tools. However, this approach is less practical and
costly for screening. The third approach oﬀers the serology
tests (EMA/tTG). These tests, regardless of their limitations,
seem to be the most cost-eﬀective approach available for
screening CD in the general population or in high-risk
groups. In this study, the prevalence of dyspepsia using
EMA/tTG was 7%, a ﬁgure higher than what has been
reported in the general population [3, 5]. Furthermore,
all patients with positive serology or histopathology in
favor of CD had the Dysmotility type functional dyspepsia
according to Rome II criteria. The pathophysiology of
the Dysmotility type dyspepsia has been attributed to
autoimmune damage to autonomous system or increase in
neurotensin or enteroglucagon levels which impair gastroin-
testinal motility [15, 16, 18]. These pathological changes
may be the mechanism that explains the higher prevalence
of CD in this subtype group of dyspeptic patients. The
higher prevalence of CD among females in our sample is
in agreement with other studies, which have shown similar
results among women [3, 12, 13]. The rationale for the latter
ﬁnding has not been clariﬁed in the literature. In our study,
more than 50% of the patients were in the Marsh stage I,
suggesting that diagnosing patients in an early stage can lead
to proper management and prevention of late and severe
complications. The reasons as to why most of the patients
in this study were in the Marsh I stage is not clear, but to
our knowledge the atypical pictures of CD in contrast to its
classical forms may have less pathologic changes of gluten
enteropathy in the gut.
This study identiﬁes a high prevalence of CD in func-
tional dyspeptic patients (7%) using diagnostic biopsy from
the second portion of the duodenum. The prevalence of CD
was higher among female patients (83.4%) and Dysmotility
type dyspepsia (50%). These ﬁndings suggest that per-
forming a routine diagnostic biopsy among at-risk patients
(i.e., functional dyspeptic patients and female patients
with dominant Dysmotility type functional dyspepsia) can
identify CD in its earliest stage and delay more complicated
life threatening and terminal complications. In developing
countries, early screening and identiﬁcation of CD in at-risk
groups can increase the level of awareness and sensitivity
of physicians in recognizing various clinical presentations of
CD and allow them to treat patients accordingly.
5. LimitationsandFutureDirections
This study oﬀers several strengths. Most prominently, it is
among the ﬁrst study that is designed to focus on occult
celiac disease among patients with functional dyspepsia.
Furthermore, the study was conducted in a geographic area
with the higher rates of CD in the world. Despite these
strengths our study is subject to several limitations. The
sample size was small and was collected only in one region
of Iran, hence limiting our ability to conduct more rigorous
statistical tests on the data, as well as limiting our ability
to generalize the study ﬁndings to a larger population in
the country or other parts of the world. Future control trial
studies with a larger sample and follow-up with gluten-
free diet are needed to conﬁrm and expand upon these
ﬁndings.
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